Notices

• Agency Information Collection Activities: Proposed Collection; Comment Request

  

• Agency Information Collection Activities: Proposed Collection; Comment Request

  

• Agency Information Collection Activities: Submission for OMB Review; Comment Request

  

• Agency Information Collection Activities: Submission for OMB Review; Comment Request

  

• Agency Information Collection Activities: Submission for OMB Review; Comment Request

  

• Medicare , Medicaid , and CLIA Programs; Clinical Laboratory Improvement Amendments of 1988 Exemption of Laboratories Licensed by the State of Washington

  

• Agency Information Collection Activities: Submission for OMB Review ; Comment Request

  

• Agency Information Collection Activities : Proposed Collection ; Comment Request

  

• Agency Information Collection Activities: Submission for OMB Review ; Comment Request

  

• Medicare Program; Application by the Utilization Review Accreditation Commission (URAC) for Continued CMS Approval of Its Home Infusion Therapy (HIT) Accreditation Program

  

• Medicare Program; Virtual Meeting of the Medicare Evidence Development and Coverage Advisory Committee-May 21, 2024

  

• Medicaid and Childrens Health Insurance Program (CHIP) Generic Information Collection Activities: Proposed Collection; Comment Request

  

• Medicare Program; Announcement of the Re-Approval of COLA Under the Clinical Laboratory Improvement Amendments of 1988

  

• Medicare and Medicaid Programs; Application From the Joint Commission for Continued CMS-Approval of Its Ambulatory Surgical Center Accreditation Program

  

• Medicare and Medicaid Programs; Quarterly Listing of Program Issuances-October Through December 2023

  

• Medicare Program; Request for Information on Medicare Advantage Data

  

• Medicare and Medicaid Programs; Application by DNV Healthcare USA Inc. (DNV) for Continued CMS Approval of Its Psychiatric Hospital Accreditation Program

  

• Federal Independent Dispute Resolution Operations; Reopening of Comment Period

  

• Meeting of the Substance Abuse and Mental Health Services Administration, Center for Mental Health Services National Advisory Council

  

• Request for Public Comment on NIOSH Initial Recommendations To Change the Status of Liraglutide and Pertuzumab on the NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings